Tumors of the Urinary System

Knapp, Deborah W.; McMillan, Sara K.

doi:10.1016/b978-1-4377-2362-5.00029-3

Cited by 58 publications

(74 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Transitional cell carcinoma (TCC) is the most common urinary tract cancer in dogs, accounting for approximately 2% of all reported canine malignancies . Most dogs exhibit haematuria, stranguria and pollakiuria at diagnosis .…”

Section: Introductionmentioning

confidence: 99%

“…Most dogs exhibit haematuria, stranguria and pollakiuria at diagnosis . Clinical signs such as pain and lameness associated with bone metastases are rarely present in dogs with TCC . Currently, because of frequent development in the trigone region, presence of undetectable microscopic tumour expansion within the bladder, and/or urethral involvement in dogs with TCC, systemic medical therapy is the mainstay of treatment .…”

Section: Introductionmentioning

confidence: 99%

“…Clinical signs such as pain and lameness associated with bone metastases are rarely present in dogs with TCC . Currently, because of frequent development in the trigone region, presence of undetectable microscopic tumour expansion within the bladder, and/or urethral involvement in dogs with TCC, systemic medical therapy is the mainstay of treatment . Most common medical therapies include administration of cyclooxygenase (COX) inhibitors alone, such as piroxicam, firocoxib or deracoxib; and administration of chemotherapeutic drugs, such as cisplatin, mitoxantrone, carboplatin, vinblastine or chlorambucil combined with COX inhibitors; the median survival time (ST) of dogs after these treatments ranged from 152 to 323 days for COX inhibitors alone and from 147 to 307 days for patients receiving a combination of chemotherapy and COX inhibitors …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Survival analysis in dogs with urinary transitional cell carcinoma that underwent whole‐body computed tomography at diagnosis

Iwasaki

Shimosato

Yoshikawa

et al. 2019

Vet Comparative Oncology

View full text Add to dashboard Cite

This retrospective study aimed to evaluate factors associated with survival and to compare characteristics between tumour localizations in dogs with urinary transitional cell carcinoma (TCC) that underwent whole‐body computed tomography (CT) at diagnosis. Dogs with histologically confirmed TCC that received medical therapy between 2010 and 2017 were included; dogs that underwent surgery or radiotherapy for the primary tumour were excluded. According to the CT findings, primary tumour localization (classified into the Bladder, Urethra and Bladder and Urethra groups), prostate involvement, iliosacral lymphadenomegaly, sternal lymphadenomegaly and metastasis to the bone and lung were evaluated for survival analysis. CT at diagnosis revealed iliosacral lymphadenomegaly, sternal lymphadenomegaly, bone metastasis and lung metastasis in 47.7%, 18.5%, 24.6% and 35.4% of the 65 included dogs, respectively. The overall median survival time was 196 days. On multivariable analysis, TCC localization (hazard ratio [HR], 1.90; P = .037), bone metastasis (HR, 2.76; P = .013) and sternal lymphadenomegaly (HR, 3.56; P = .004) were significantly associated with survival. Compared to the Bladder group (n = 16), the Urethra group (n = 26) had higher metastasis rates to the bone (6.3% vs 42.3%; P = .045) and lung (6.3% vs 46.2%; P = .022). The survival time was shorter in the Urethra group than in the Bladder group (121.5 vs 420 days; P < .001), and it was similar only in female dogs (247 vs 420 days; P = .031). These findings suggest that whole‐body CT could be valuable for predicting the prognosis in urinary TCC.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Survival analysis in dogs with urinary transitional cell carcinoma that underwent whole‐body computed tomography at diagnosis

Iwasaki

Shimosato

Yoshikawa

et al. 2019

Vet Comparative Oncology

View full text Add to dashboard Cite

show abstract

“…Transitional cell carcinoma (TCC), also known as urothelial carcinoma, accounts for approximately 1% to 2% of all canine malignant tumours and is the most common tumour affecting the urinary tract in dogs . Because of nonspecific clinical signs such as hematuria, pollakiuria, and stranguria, early detection of canine TCC is rare.…”

Section: Introductionmentioning

confidence: 99%

“…Because of nonspecific clinical signs such as hematuria, pollakiuria, and stranguria, early detection of canine TCC is rare. By the time of diagnosis, in most cases of canine TCC, the cancer has invaded the bladder wall, with 20% of cases displaying invasion into neighbouring organs as well as distant metastasis . Curative‐intent surgery has demonstrated limited benefit in canine TCC.…”

Section: Introductionmentioning

confidence: 99%

Anti‐tumour effect of lapatinib in canine transitional cell carcinoma cell lines

Sakai

Maeda

Saeki

et al. 2018

Vet Comparative Oncology

View full text Add to dashboard Cite

Transitional cell carcinoma (TCC) accounts for >90% of canine malignant tumours occurring in urinary bladder, and the prognosis is poor. Our previous study, using RNA sequencing, showed that human epidermal growth factor 2 (HER2) was the most activated upstream regulator related to carcinogenesis in canine TCC. The aim of this study was to examine the anti‐tumour effect of lapatinib, a tyrosine kinase inhibitor of HER2, on canine TCC cell lines in vitro and in vivo. Five canine TCC cell lines (TCCUB, Love, Sora, LCTCC, and MCTCC) were used. Western blotting showed that HER2 protein expression was observed in all of the canine TCC cell lines. Lapatinib inhibited phosphorylation of HER2 and cell growth in a dose‐dependent manner. Cell cycle analyses using flow cytometry showed that lapatinib significantly increased the sub‐G1 and G0/G1 phase fractions and significantly decreased the S and G2/M phase fractions in the cell lines (Sora and TCCUB). For the in vivo experiments, the canine TCC cells (Sora) were subcutaneously injected into nude mice. Six days after inoculation, lapatinib (100 mg/kg) or vehicle was administered daily via intraperitoneal administration for 14 days. Tumour volume was significantly smaller in the lapatinib group compared with the vehicle control group. Histologically, lapatinib significantly increased necrotic areas in the tumour tissues. These findings suggest that lapatinib exerts anti‐tumour effects on canine TCC cells by inhibiting HER2 signalling and inducing cell cycle arrest.

show abstract

Oncology for the Interventionalist

Mullin¹,

Clifford

2015

Veterinary Image‐Guided Interventions

View full text Add to dashboard Cite

Tumors of the Urinary System

Cited by 58 publications

References 79 publications

Survival analysis in dogs with urinary transitional cell carcinoma that underwent whole‐body computed tomography at diagnosis

Survival analysis in dogs with urinary transitional cell carcinoma that underwent whole‐body computed tomography at diagnosis

Anti‐tumour effect of lapatinib in canine transitional cell carcinoma cell lines

Oncology for the Interventionalist

Contact Info

Product

Resources

About